Weekly Digest – May 2025 Weekly Digest – May 2025 29 May 2025: China’s HER2-targeted ADC Trastuzumab Rezetecan gains NMPA approval for HER2-mutant NSCLC China approved Trastuzumab rezetecan, its first domestically developed antibody-drug conjugate (ADC), for treating HER2-mutant advanced non-small […]
Weekly Digest – May 2025 Weekly Digest – May 2025 28 May 2025: Experimental Drug Development Centre granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to treat pancreatic ductal adenocarcinoma EBC-129 is the first Singapore-made antibody-drug conjugate (ADC) […]
Weekly Digest – May 2025 Weekly Digest – May 2025 23 May 2025: Blenrep (belantamab mafodotin) combinations receive positive CHMP opinion in relapsed/refractory multiple myeloma CHMP of EMA recommended approval of Blenrep for relapsed/refractory multiple myeloma in combinations BVd (for […]
Weekly Digest – May 2025 Weekly Digest – May 2025 29 May 2025: Patritumab Deruxtecan biologics license application (BLA) for patients with previously treated locally advanced or metastatic EGFR-mutated non-small cell lung cancer voluntarily withdrawn Daiichi Sankyo and Merck voluntarily […]
Weekly Digest – May 2025 Weekly Digest – May 2025 23 May 2025: ASCENT-03: Trodelvy demonstrates highly statistically significant & clinically meaningful improvement in progression free survival in patients with first-line metastatic TNBC who are not candidates for checkpoint inhibitors […]
Weekly Digest – May 2025 Weekly Digest – May 2025 30 May 2025: Astellas enters exclusive license agreement with Evopoint Biosciences for XNW27011, a novel clinical-stage ADC Targeting CLDN18.2 Astellas Pharma has secured exclusive worldwide rights (excluding Greater China) to […]
